Hospira in US-wide recall of product due to contamination

pharmafile | January 25, 2017 | News story | Medical Communications Contamination, Hospira, Pfizer 

Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence of particulate matter within a single vial”. What exactly was found is not clear, but a customer apparently called the matter to Hospira’s attention and it immediately announced a voluntary recall.

The side-effects of anyone using Vancomycin Hydrochloride, an antibiotic to fight bacteria in the intestines, with the particular contamination were announced to be “local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate.” To date, there have been no adverse reactions to the faulty batch of drugs but this has not prevented Hospira from taking action.

It is particularly embarrassing for the company, which was forced to recall anaesthetic in August of last year due, again, to a ‘particulate matter’ being found in a vial of the drug, bupivacaine hydrochloride injection. On this particular occasion, the faulty product was produced at Rocky Mount manufacturing facility, which has been linked to a string of faulty products being launched.

Advertisement

It is not clear whether the current recall is from the same location but a letter has been issued to all customers worldwide to notify them of the dates that the faulty products lie under.

Ben Hargreaves

Related Content

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …

The Gateway to Local Adoption Series

Latest content